Disclaimer: Statistical patterns flagged for review only. This tool does not determine or imply wrongdoing. All findings require independent verification.
Risk Score
Forensic risk score: 0 out of 100. LOW RISK.
0RISK SCORE
LOW RISKCompliance
N/A/100
Awards
4
Total Value
R 324M
Recent Awards
4 awards · Total: R 324 482 829
HP02-2025AI: Supply and Delivery of Anti-Infective Medicines (Antibiotics, Antifungal, Antiprotozoal and Antiviral Agents) to the Department of Health for the period 1 October 2025 to 30 September 2028.
Health
Ref: HP02-2025AIR 218 293 010
21 Aug 2025
Supply and Delivery of Anti-Infective Medicines (Antibiotics, Antifungal, Antiprotozoal and Antiviral Agents) to the Department of Health for the period 1 October 2023 to 30 September 2025
Health
Ref: HP02-2023AIR 74 086 831
15 Jun 2023
SUPPLY AND DELIVERY OF PHARMACEUTICAL PRODUCTS: DROPS, AEROSOLS AND INHALED MEDICINES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 JULY 2023 TO 30 JUNE 2026
ERRATUM 1: PLEASE NOTE THAT THE SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT (SRCC) AS PUBLISHED WITH THE BID PACK ON 17 JUNE 2022 FOR TENDER HP07-2023DAI IS BEING REPLACED WITH THIS ERRATUM.
Health
Ref: HP07-2023DAIR 21 497 064
13 Feb 2023
SUPPLY AND DELIVERY OF SEMI-SOLID DOSAGE FORMS AND POWDERS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 JULY 2023 TO 30 JUNE 2026
ERRATUM 1: PLEASE NOTE THAT THE SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT (SRCC) AS PUBLISHED WITH THE BID PACK ON 17 JUNE 2022 FOR TENDER HP08-2023SSP IS BEING REPLACED WITH THIS ERRATUM.
Health
Ref: HP08-2023SSPR 10 605 923
13 Feb 2023
AI Analysis
Powered by GeminiAI Forensic Analysis
Get AI-generated audit narratives with key findings and recommended actions.
Paid access from R499/mo
or upgrade to Pro Subscription
Risk Assessment
Forensic risk score: 0 out of 100. LOW RISK.
0RISK SCORE
LOW RISKBased on 0 forensic flags detected
Unlock Full Analysis
Get access to all forensic flags, evidence details, and AI-generated audit narratives.
View Full Intelligence Report
Get complete award history, director network, and compliance analysis.
View Report →